India's Approach To Pharma Patents Under US Attack, But Other BRICS Nations Likely To Adopt It

from the closing-the-barn-door dept

Techdirt has been reporting for a while on India's growing success in providing its population with access to low-cost generic drugs, making use of the permissions to do so granted by TRIPS. That has naturally earned it the ire of Western pharma companies, which now seem to be striking back, as this post on Infojustice.org explains:

The U.S. pharmaceutical industry and its Big Brother Chamber of Commerce have launched an all-out disinformation campaign against the India Patent Act and decisions rendered thereunder. They have enlisted allies in the U.S. government, including Members of Congress, the United States International Trade Commission, Secretary of State Kerry, and even President Obama, to carry their claims to the highest levels of the Indian government. They have threatened to insist that the U.S. file a WTO trade complaints against India in 2014 and that India no longer be permitted to export duty-free products to the U.S. under the Generalized System of Preferences.

As evidence for their campaign, the representatives of Big Pharma have claimed that India is violating US-based global norms for protecting patent rights, that it is adopting new patenting criteria not authorized by international law and allowing generic competition when it is not permissible, and that it is discriminating against U.S. pharmaceutical companies in favor protectionist policies that shield Indian generic companies and steal U.S. jobs.
The rest of the post -- written by Professor Brook K. Baker, whose work has been discussed here on Techdirt several times -- then goes on to explain in detail why those claims are false, and is well-worth reading to understand the legal issues here.

Interestingly, it looks like India could be joined by other nations in exploiting TRIPS flexibilities. An article in South Africa's Mail & Guardian newspaper reports that there is both legislation and a detailed report from the research arm of the Brazilian Chamber of Deputies that have this as their goal, not just in Brazil, but elsewhere too:

Amending intellectual property legislation is just what the country aims to do with the release of a 363-page report earlier this week by the Brazilian [Chamber of Deputies] Centre for Strategic Studies and Debates.

The report's suggested changes mirror those outlined in a Bill tabled in Brazil's Parliament earlier this year.

Although the Bill has yet to be heard, lead report writer Pedro Paranaguà, intellectual property adviser for the ruling Workers Party, says that he hopes the document "will serve as a means for influencing court decisions, the competition authority, and academics -- nationally, and internationally".
In the same article, Baker explains why India succeeded in creating a flourishing domestic drug industry, while Brazil did not:
Although developing countries had until 2005 to adopt the Trips Agreement into their national laws, Baker says that Brazil acceded nearly a decade earlier because the US pressured the country into adopting more stringent intellectual property measures by placing it on its Special 301 Report.



India, in contrast, waited until the 2005 deadline. As such, the country did not have to respect pharmaceutical patents, which helped India to develop a strong generic pharmaceutical sector. The country is now famously known as the "pharmacy of the developing world", supplying the majority of the [antiretroviral drugs] used in Africa.
Meanwhile, in South Africa, an open letter from 130 organizations and experts to the Department of Trade and Industry there is urging similar pro-health patent moves to those in Brazil:
South Africa's Department of Trade and Industry (DTI) has expressed its intention that reform of the intellectual property system will balance patients' rights with those of patent-holders. Given South Africa's high burden for both communicable and non-communicable diseases, this is a positive step towards addressing the current imbalance in the system in a manner conducive to social and economic welfare, the protection of public health, and the transfer and dissemination of technology, especially in sectors of vital importance to socio-economic and technological development. The DNPIP [Draft National Policy on Intellectual Property] proposes several reforms that would make use of pro-public health flexibilities allowable under the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property (TRIPS). Many other countries, including India and Argentina, have already incorporated TRIPS flexibilities into their national laws, and others, like Brazil, are initiating comparable pro-health patent law reforms. These countries and others have also implemented TRIPS-compliant flexibilities to procure more affordable medicines and to strengthen domestic pharmaceutical capacity. We think that intellectual property law reforms are essential for South Africa to meet its human rights obligations, including the right to health and the right of access to medicines.
This is doubtless exactly what Western pharma companies feared would happen. India's example is now inspiring other BRICS countries to follow suit, making use of flexibilities in TRIPS to provide desperately-need medicines to their populations at affordable prices. Current US attempts to attack India's approach to pharma patents are not just unjustified, as Baker explains, but quite simply too late.

Follow me @glynmoody on Twitter or identi.ca, and on Google+

Hide this

Thank you for reading this Techdirt post. With so many things competing for everyone’s attention these days, we really appreciate you giving us your time. We work hard every day to put quality content out there for our community.

Techdirt is one of the few remaining truly independent media outlets. We do not have a giant corporation behind us, and we rely heavily on our community to support us, in an age when advertisers are increasingly uninterested in sponsoring small, independent sites — especially a site like ours that is unwilling to pull punches in its reporting and analysis.

While other websites have resorted to paywalls, registration requirements, and increasingly annoying/intrusive advertising, we have always kept Techdirt open and available to anyone. But in order to continue doing so, we need your support. We offer a variety of ways for our readers to support us, from direct donations to special subscriptions and cool merchandise — and every little bit helps. Thank you.

–The Techdirt Team

Filed Under: india, patents, pharmaceuticals, trips, us


Reader Comments

Subscribe: RSS

View by: Thread


  1. identicon
    Anonymous Coward, 1 Nov 2013 @ 4:50am

    Re:

    This is what has led to what I would term "Imaginary Bloat" in the US IP systems: the bloat in tweaking current IPs such that they can be re-applied in a new fashion, thus resetting the 'expiration clock' on all sorts of things, from biotech to cloud computing to wireless transmissions.

    And it is this that will lead to America's fall from grace in this arena - they've essentially become 'too big to compete' for the most part, and thus resort to childish and incorrect strategic applications of its might.

Add Your Comment

Have a Techdirt Account? Sign in now. Want one? Register here



Subscribe to the Techdirt Daily newsletter




Comment Options:

  • Use markdown. Use plain text.
  • Remember name/email/url (set a cookie)

Follow Techdirt
Special Affiliate Offer

Essential Reading
Techdirt Deals
Report this ad  |  Hide Techdirt ads
Techdirt Insider Chat

Warning: include(/home/beta6/deploy/itasca_20201215-3691-c395/includes/right_column/rc_promo_jq_chat.inc): failed to open stream: No such file or directory in /home/beta6/deploy/itasca_20201215-3691-c395/includes/right_column/rc_module_promo.inc on line 8

Warning: include(): Failed opening '/home/beta6/deploy/itasca_20201215-3691-c395/includes/right_column/rc_promo_jq_chat.inc' for inclusion (include_path='.:/usr/share/pear:/home/beta6/deploy/itasca_20201215-3691-c395:/home/beta6/deploy/itasca_20201215-3691-c395/..') in /home/beta6/deploy/itasca_20201215-3691-c395/includes/right_column/rc_module_promo.inc on line 8

Warning: include(/home/beta6/deploy/itasca_20201215-3691-c395/includes/right_column/rc_promo_discord_chat.inc): failed to open stream: No such file or directory in /home/beta6/deploy/itasca_20201215-3691-c395/includes/right_column/rc_module_promo.inc on line 8

Warning: include(): Failed opening '/home/beta6/deploy/itasca_20201215-3691-c395/includes/right_column/rc_promo_discord_chat.inc' for inclusion (include_path='.:/usr/share/pear:/home/beta6/deploy/itasca_20201215-3691-c395:/home/beta6/deploy/itasca_20201215-3691-c395/..') in /home/beta6/deploy/itasca_20201215-3691-c395/includes/right_column/rc_module_promo.inc on line 8
Recent Stories
.

This site, like most other sites on the web, uses cookies. For more information, see our privacy policy. Got it
Close

Email This

This feature is only available to registered users. Register or sign in to use it.